Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Tourette Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Tourette Syndrome - Pipeline Review, H2 2014', provides an overview of the Tourette Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tourette Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Tourette Syndrome - Overview 8 Pipeline Products for Tourette Syndrome - Comparative Analysis 9 Tourette Syndrome - Therapeutics under Development by Companies 10 Tourette Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Tourette Syndrome - Products under Development by Companies 16 Tourette Syndrome - Companies Involved in Therapeutics Development 17 AstraZeneca PLC 17 Neurocrine Biosciences, Inc. 18 Catalyst Pharmaceutical Partners, Inc. 19 Auspex Pharmaceuticals, Inc. 20 Edison Pharmaceuticals, Inc. 21 Otsuka Holdings Co., Ltd. 22 Reviva Pharmaceuticals Inc. 23 Psyadon Pharmaceuticals, Inc. 24 Tourette Syndrome - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 33 aripiprazole - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ecopipam hydrochloride - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AZD-5213 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 vigabatrin - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 vatiquinone - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 dutetrabenazine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 valbenazine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 RP-5063 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Tourette Syndrome - Recent Pipeline Updates 48 Tourette Syndrome - Dormant Projects 61 Tourette Syndrome - Discontinued Products 62 Tourette Syndrome - Product Development Milestones 63 Featured News & Press Releases 63 May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17 63 Sep 24, 2012: Catalyst Pharma Announces Initiation Of CPP-109 Investigator-Sponsored Study In Patients With Treatment Refractory Tourette's Disorder 63 Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 64 Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome 65 Feb 09, 2012: Catalyst Files US Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-109 In Treatment Of Tourette Syndrome 66 Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 66 May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 67 Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 67 Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 68 Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 70 Disclaimer 70
List of Tables Number of Products under Development for Tourette Syndrome, H2 2014 8 Number of Products under Development for Tourette Syndrome - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Comparative Analysis by Unknown Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Tourette Syndrome - Pipeline by AstraZeneca PLC, H2 2014 17 Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H2 2014 18 Tourette Syndrome - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 19 Tourette Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 20 Tourette Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 21 Tourette Syndrome - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 22 Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 23 Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 32 Tourette Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 48 Tourette Syndrome - Dormant Projects, H2 2014 61 Tourette Syndrome - Discontinued Products, H2 2014 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
